Pancreatic Cancer Research

ResearcherKindai University HospitalActive in the last 2 years

Ken Kamata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1568-0769; OpenAlex author ID A5020690509, A5020883439, A5036817380. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 21

  1. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  2. Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. Co-author DOI 10.1016/j.pan.2025.02.013↗
  3. Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomiz… Co-author DOI 10.1002/jgh3.12966↗
  4. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  5. Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. Co-author DOI 10.1007/s10147-023-02396-w↗
  6. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  7. Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter p… Co-author DOI 10.1007/s10147-022-02160-6↗
  8. Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. First author DOI 10.4103/eus-d-21-00185↗
  9. Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). Co-author DOI 10.1016/j.gie.2020.06.051↗
  10. Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings. Co-author DOI 10.3390/diagnostics11101858↗
  11. Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Loca… Co-author DOI 10.3390/diagnostics10070445↗
  12. Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. First author DOI 10.1016/j.dld.2019.03.015↗
  13. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrosp… Co-author DOI 10.2169/internalmedicine.2234-18↗
  14. Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gie.2017.05.052↗
  15. Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. Co-author DOI 10.3390/cancers10020050↗
  16. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1159/000481234↗
  17. EUS-Guided Pancreatic Duct Drainage for Repeat Pancreatitis in a Patient with Pancreatic Cancer. Co-author DOI 10.1159/000481238↗
  18. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. Co-author DOI 10.3892/ijo.2017.3961↗
  19. [A Case of Conversion Surgery for a Patient with Initially Unresectable Pancreatic Cancer with a Pathological Complete Response to S-1 Chemotherapy]. Co-author PMID 29394577↗
  20. Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. Co-author DOI 10.1177/1756283x16644248↗
  21. Endoscopic ultrasound-guided neurolysis in pancreatic cancer. Co-author DOI 10.1159/000323513↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masatoshi Kudo · 17 shared papers, 2011–2025 · strength 1.67
  2. Kosuke Minaga · 15 shared papers, 2016–2025 · strength 1.57
  3. Mamoru Takenaka · 14 shared papers, 2017–2025 · strength 1.52
  4. Kentaro Yamao · 13 shared papers, 2016–2025 · strength 1.35
  5. Atsushi Nakai · 8 shared papers, 2017–2023 · strength 0.74
  6. Masayuki Kitano · 8 shared papers, 2011–2023 · strength 0.69
  7. Ippei Matsumoto · 6 shared papers, 2017–2022 · strength 0.51
  8. Hidekazu Tanaka · 4 shared papers, 2019–2023 · strength 0.46
  9. Yoshifumi Takeyama · 5 shared papers, 2017–2022 · strength 0.40
  10. Junki Mizusawa · 2 shared papers, 2023–2026 · strength 0.33
  11. Yoshito Komatsu · 2 shared papers, 2023–2026 · strength 0.33
  12. Satoshi Kobayashi · 2 shared papers, 2023–2026 · strength 0.33
  13. Masafumi Ikeda · 2 shared papers, 2023–2026 · strength 0.33
  14. Yukiko Takayama · 2 shared papers, 2023–2026 · strength 0.33
  15. Masato Ozaka · 2 shared papers, 2023–2026 · strength 0.33
  16. Junji Furuse · 2 shared papers, 2023–2026 · strength 0.33
  17. Nao Fujimori · 2 shared papers, 2023–2026 · strength 0.33
  18. Makoto Ueno · 2 shared papers, 2023–2026 · strength 0.33
  19. Takuji Okusaka · 2 shared papers, 2023–2026 · strength 0.33
  20. Naoki Sasahira · 2 shared papers, 2023–2026 · strength 0.33
  21. Masakatsu Tsurusaki · 3 shared papers, 2020–2021 · strength 0.32
  22. Yasuo Otsuka · 2 shared papers, 2022–2023 · strength 0.28
  23. Kazuto Nishio · 2 shared papers, 2017–2023 · strength 0.22
  24. Tadashi Iida · 1 shared paper, 2025 · strength 0.22
  25. Takuya Ishikawa · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.